These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 34169074)

  • 1. The Interdisciplinary Stem Cell Institute's Use of Food and Drug Administration-Expanded Access Guidelines to Provide Experimental Cell Therapy to Patients With Rare Serious Diseases.
    Khan A; Bellio MA; Schulman IH; Levi AD; Longsomboon B; Brooks A; Valasaki K; DiFede DL; Pujol MV; Yavagal DR; Bates KE; Si MS; Kaushal S; Green BA; Anderson KD; Guest JD; Burks SS; Silvera R; Santamaria AJ; Lalwani A; Dietrich WD; Hare JM
    Front Cell Dev Biol; 2021; 9():675738. PubMed ID: 34169074
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ten-Year Experience for the Center for Drug Evaluation and Research, Part 2: FDA's Role in Ensuring Patient Safety.
    Jarow JP; Lemery S; Bugin K; Lowy N
    Ther Innov Regul Sci; 2017 Mar; 51(2):246-249. PubMed ID: 28553566
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bone Marrow Concentrate (BMC) Therapy in Musculoskeletal Disorders: Evidence-Based Policy Position Statement of American Society of Interventional Pain Physicians (ASIPP).
    Manchikanti L; Centeno CJ; Atluri S; Albers SL; Shapiro S; Malanga GA; Abd-Elsayed A; Jerome M; Hirsch JA; Kaye AD; Aydin SM; Beall D; Buford D; Borg-Stein J; Buenaventura RM; Cabaret JA; Calodney AK; Candido KD; Cartier C; Latchaw R; Diwan S; Dodson E; Fausel Z; Fredericson M; Gharibo CG; Gupta M; Kaye AM; Knezevic NN; Kosanovic R; Lucas M; Manchikanti MV; Mason RA; Mautner K; Murala S; Navani A; Pampati V; Pastoriza S; Pasupuleti R; Philip C; Sanapati MR; Sand T; Shah RV; Soin A; Stemper I; Wargo BW; Hernigou P
    Pain Physician; 2020 Mar; 23(2):E85-E131. PubMed ID: 32214287
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FDA's proposed regulations to expand access to investigational drugs for treatment use: the status quo in the guise of reform.
    Rossen BR
    Food Drug Law J; 2009; 64(1):183-223. PubMed ID: 19998746
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expanding Patient Access to Investigational Drugs: Single Patient Investigational New Drug and the "Right to Try".
    Van Norman GA
    JACC Basic Transl Sci; 2018 Apr; 3(2):280-293. PubMed ID: 30062214
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overview of FDA's Expanded Access Program for Investigational Drugs.
    Jarow JP; Lurie P; Ikenberry SC; Lemery S
    Ther Innov Regul Sci; 2017 Mar; 51(2):177-179. PubMed ID: 28553565
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expanding Patient Access to Investigational New Drugs: Overview of Intermediate and Widespread Treatment Investigational New Drugs, and Emergency Authorization in Public Health Emergencies.
    Van Norman GA
    JACC Basic Transl Sci; 2018 Jun; 3(3):403-414. PubMed ID: 30062226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An FDA analysis of clinical hold deficiencies affecting investigational new drug applications for oncology products.
    Manning ML; Thompson MD; Saber H; Maher VE; Crich JZ; Leighton JK
    Regul Toxicol Pharmacol; 2020 Feb; 110():104511. PubMed ID: 31678263
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncology Expanded Access and FDA's Project Facilitate.
    Scepura B; Chan M; Kim T; Boehmer J; Goldberg KB; Pazdur R
    Oncologist; 2021 Oct; 26(10):e1880-e1882. PubMed ID: 34288259
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Providing Patients with Critical or Life-Threatening Illnesses Access to Experimental Drug Therapy: A Guide to Clinical Trials and the US FDA Expanded Access Program.
    Speers MA
    Pharmaceut Med; 2019 Apr; 33(2):89-98. PubMed ID: 31933253
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Access to Investigational Drugs: FDA Expanded Access Programs or "Right-to-Try" Legislation?
    Holbein ME; Berglund JP; Weatherwax K; Gerber DE; Adamo JE
    Clin Transl Sci; 2015 Oct; 8(5):526-32. PubMed ID: 25588691
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Availability of Investigational Medicines Through the US Food and Drug Administration's Expanded Access and Compassionate Use Programs.
    Puthumana J; Miller JE; Kim J; Ross JS
    JAMA Netw Open; 2018 Jun; 1(2):e180283. PubMed ID: 30646072
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retrospective evaluation of single patient investigational new drug (IND) requests in pediatric oncology.
    Shulman DS; Kiwinda LV; Edwards S; Clinton CM; Hunt S; Greenspan L; Lawler KD; Reaman G; Al-Sayegh H; Bona K; O'Neill AF; Shusterman S; Janeway KA; Place AE; Chi SN; Ma C; DuBois SG
    Cancer Med; 2021 Apr; 10(7):2310-2318. PubMed ID: 33751835
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FDA efficiency for approval process of COVID-19 therapeutics.
    Cassidy C; Dever D; Stanbery L; Edelman G; Dworkin L; Nemunaitis J
    Infect Agent Cancer; 2020 Dec; 15(1):73. PubMed ID: 33292374
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expanded Patient Access to Investigational New Devices: Review of Emergency and Nonemergency Expanded Use, Custom, and 3D-Printed Devices.
    Van Norman GA
    JACC Basic Transl Sci; 2018 Aug; 3(4):533-544. PubMed ID: 30175277
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expanded Access of Investigational Drugs: The Experience of the Center of Drug Evaluation and Research Over a 10-Year Period.
    Jarow JP; Lemery S; Bugin K; Khozin S; Moscicki R
    Ther Innov Regul Sci; 2016 Nov; 50(6):705-709. PubMed ID: 27917324
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Iodine-131 Tositumomab: (131)I-anti-B1 antibody, (131)I-tositumomab, anti-CD20 murine monoclonal antibody-I-131, B1, Bexxar, (131)I-anti-B1 antibody, iodine-131 tositumomab, iodine-131 anti-B1 antibody, tositumomab.
    BioDrugs; 2003; 17(4):290-5. PubMed ID: 12899647
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expanded access to investigational drugs for treatment use. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2009 Aug; 74(155):40900-45. PubMed ID: 19691173
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized clinical trial: expanded autologous bone marrow mesenchymal cells combined with allogeneic bone tissue, compared with autologous iliac crest graft in lumbar fusion surgery.
    García de Frutos A; González-Tartière P; Coll Bonet R; Ubierna Garcés MT; Del Arco Churruca A; Rivas García A; Matamalas Adrover A; Saló Bru G; Velazquez JJ; Vila-Canet G; García-Lopez J; Vives J; Codinach M; Rodriguez L; Bagó Granell J; Càceres Palou E
    Spine J; 2020 Dec; 20(12):1899-1910. PubMed ID: 32730985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Update to Drugs, Devices, and the FDA: How Recent Legislative Changes Have Impacted Approval of New Therapies.
    Van Norman GA
    JACC Basic Transl Sci; 2020 Aug; 5(8):831-839. PubMed ID: 32864509
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.